Pramipexole, sold under the brand Mirapex among others, is medication used to treat Parkinsons disease (PD) and restless legs syndrome (RLS). In Parkinsons disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.Studies have shown detrimental side effects resulting from off-label use of pramipexole or other dopamine agonists in treating clinical depression.Pramipexole was approved for medical use in the United States in 1997. Use in pregnancy and breastfeeding is of unclear safety. It is available as a generic medication. In 2019, it was the 166th most commonly prescribed medication in the United States, with more than 3 million prescriptions. Medical uses
Pramipexole is used in the treatment of Parkinsons disease (PD) and restless legs syndrome (RLS). Use in pregnancy and breastfeeding is of unclear safety.It is occasionally prescribed off-label for depression. Its effectiveness as an antidepressant may be a product of its strong partial agonistic activity on and preferential occupation of dopamine D3 receptors at low doses (see table below); as well, the drug has been shown to desensitize the inhibitory D22 autoreceptors but not the postsynaptic D2 receptors, leading to an increase in dopamine and serotonin levels in the prefrontal cortex.
Compensatory mechanism for metabolic alkalosis involve slowed breathing by the lungs to increase serum carbon dioxide, a condition leaning toward respiratory acidosis. As respiratory acidosis often accompanies the compensation for metabolic alkalosis, and vice versa, a delicate balance is created between these two conditions. See also
References
External links

IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "alkalosis". doi:10.1351/goldbook.A00221